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Background. Recent publications have highlighted the benefits of statins in non-cardiac occlusive disease but also the failure
of vascular surgeons to recognise and treat the risk factors for atherosclerosis, in particular hypercholesterolaemia. The aim of
this review is to clarify the current experimental and clinical evidence for the use of statins in vascular disease.
Methods. Literature compiled from an extensive search of Medline and the Cochrane database has been used for the basis of
this review.
Results. Experimental and clinical evidence consistently reports that statins improve endothelial dysfunction, are anti-
inflammatory, anti-proliferative, anti-thrombogenic and anti-proteolytic. These effects are known to inhibit atherogenesis
and improve plaque stability. Independent groups support the use of statins in the prevention of both primary and secondary
cardiac events. The National Stroke association recommends their use to reduce strokes following myocardial infarction and
the Heart Protection Study reports benefits in patients with non-cardiac occlusive disease.
Conclusions. There is substantial evidence advocating the use of statins in patients with clinically significant vascular
disease. In the future this may evolve to include those patients at risk from neointimal hyperplasia, aneurysmal disease and
ischaemia reperfusion injury.
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Introduction
Historical aspects and pharmacology
Endo and Kuroda discovered statins in 1973 by
searching for microbial metabolites that would compe-
titively inhibit HMG-CoA reductase, the rate-limiting
step in the synthesis of cholesterol (Fig. 1).1 Having
examined over 6000 microbial strains, the antibiotic
Citrinin was isolated from Pythium ultimum and later
mevastatin from Penicillium Citrinum. This led to the
development of mevastatin analogues namely lova-
statin, simvastatin and pravastatin as well as others.
The discovery and development of statins is summar-
ized in a review article published in 1992.2
The extensive comparative pharmacology of statins,
including their absorption, bioavailability, distri-
bution, metabolism and excretion has been reported
by others.3 In brief, lovastatin and simvastatin are both
lactone pro-drugs that are hydrolysed in vivo to
produce their active open ring b-hydroxy acid form.
Simvastatin, lovastatin, fluvastatin and atorvastatin are
lipophilic and therefore freely diffuse into cells. In
contrast, pravastatin is hydrophilic and enters cells
using specific transport mechanisms. With the exception
of atorvastatin, they all have relatively short half-lives
(a reflection of their extensive first pass metabolism in the
liver), which prevents accumulation with repeat dosing.
This short half-life of 0.5–3 h does not correspond to the
duration of their pharmaco-dynamic effect, which is of
the order of 24 h and is prolonged by the production of
active metabolites. All of the statins, with the exception
of pravastatin, are extensively protein-bound (predomi-
nantly to albumin), limiting the systemic exposure to the
pharmacologically active drug. Although the levels of
unbound pravastatin are greater, its hydrophilic
nature limits widespread tissue distribution.
Statins, lipid profile and the regulation of HMG-CoA
reductase
Cells acquire cholesterol by de novo synthesis and the
uptake and degradation of plasma lipo-proteins via
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LDL-receptors. The delivery of cholesterol to the cell
results in the down regulation of its’ own synthesis
and decreased expression of LDL receptors.4 Statins
competitively inhibit HMG-CoA reductase, thereby
decreasing cholesterol synthesis.2 This stimulates the
transcription of LDL receptors, increasing the acqui-
sition of lipids4 and decreases plasma lipid levels.5 The
metabolic pathway to cholesterol synthesis, including
some of the important intermediates and potential
feedback mechanisms, is summarized in Fig. 1. Meta-
analysis of randomised placebo-controlled trials has
shown that statin therapy is associated with a mean
reduction in serum concentration of total cholesterol of
20%, LDL cholesterol of 28% and triglycerides of 13%,
with an increase in HDL cholesterol of 5%.6
Non-sterol effects of statins
As indicated in Fig. 1, mevalonate metabolism yields
the isoprenoid intermediates, farnesyl and geranyl-
geranyl phyrophosphate. These intermediates are
essential for the post-translational modification of
G-proteins (guanosine tri-phosphate binding proteins
(GTP-ases)). This modification, collectively known as
isoprenylation, permits the translocation and covalent
attachment of G-proteins to the cell membrane and is
necessary for normal cellular function.7 In mammals,
there are over 60 G-proteins which are small, low
molecular weight proteins that, by acting as molecular
switches, control a host of biological functions.8 The
most extensively studied of these proteins are the Rho
protein family, which collectively regulate the actin
cytoskeleton. In doing so, they influence endothelial
function, smooth muscle cell contraction, platelet
activation,9 leukocyte migration and cellular
adhesion10 (Fig. 2). Inhibition of the association of
G-proteins to the cellular membrane is therefore likely
to play a prominent role in vascular homeostasis and is
responsible for the majority of the non-sterol effects of
statins.11,12
Atherogenesis
Atherogenesis is a complex process involving lipid
metabolism, haemodynamic forces, the extracellular
matrix, cytokines, endothelial, inflammatory and
smooth muscle cells.13 Hypercholesterolaemia is
associated with impaired endothelial function.14
More specifically, oxidized LDL impairs vasomotor
responses, inactivates nitric oxide (NO), reduces the
transcription of endothelial nitric oxide synthase
(eNOS) and decreases the stability of eNOS mRNA.
In addition to the effects mediated via NO, oxidized
LDL also up-regulates nuclear factor kappa-B
(NFkB),15 a key activator of cytokine transcription.
Statins reduce plasma LDL, inhibit its oxidation and
restore vasomotor responses.16,17 The effects of statins
extend far beyond lipid lowering, influencing numer-
ous mechanisms of atherogenesis.18,19 Studies have
demonstrated the capacity of statins to improve
endothelial function independent of LDL and prior
to plaque regression,16 effects that reduce the risk of
cardiovascular events beyond that anticipated from
cholesterol lowering alone.20,21 The experimental
evidence for the non-cholesterol lowering effects of
statins are discussed below and summarized in Fig. 3.
Haemodynamics (nitric oxide, endothelin and calcium
homeostasis)
Endothelial nitric oxide mediates vascular relax-
ation,22 inhibits platelet aggregation,23 smooth muscle
cell proliferation24 and endothelial-leukocyte inter-
actions.25 Oxidized LDL inhibits the expression of
eNOS26 and the synthesis of NO.27 Statins increase
eNOS mRNA stability, leading to increased eNOS
Fig. 1. Metabolic pathways to synthesis and acquisition of
cholesterol. Cholesterol synthesis results in negative feed-
back (clear boxes), resulting in reduced synthesis of
cholesterol and also reduced acquisition from plasma LDL
via the LDL receptor. Statins competitively inhibit HMG-
CoA reductase activity, thereby reducing cholesterol syn-
thesis. The reduction in cholesterol synthesis releases the
LDL receptor from negative feedback mediated by choles-
terol, resulting in elevated acquisition of cholesterol and thus
reduced plasma LDL levels.
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activity,28 a reduction in the degree of hypoxia-
mediated endothelial dysfunction29 and increased
cerebral perfusion.30 Statins also activate the protein
kinase, Akt, a well-recognized activator of eNOS,31
inhibit endothelin-1, a potent vasoconstrictor32 and
decrease the mobilization of Ca2þ and hence the
Smooth muscle cell (SMC) response to phenylephrine
and angiotensin II.33
Inflammation, cytokines, chemotaxis and adhesion
Atherosclerosis, plaque rupture and acute coronary
syndromes are all associated with pro-inflammatory
cytokines,34 chemotaxis and the up-regulation of
adhesion molecules, leading to inflammatory cell
infiltration.35 Statins inactivate NFkB,36 normally a
key activator of cytokine transcription,37 inhibiting the
expression of numerous pro-inflammatory cyto-
kines.38,39 They also inhibit the affinity of endothelial
cell inflammatory cell interactions by decreasing
receptor clustering40 adhesion molecule expression41
and by their direct binding to integrin receptors on the
endothelium.42 These mutual effects of statins inhibit
monocyte endothelial cell interactions43,44 and prevent
monocyte and neutrophil infiltration.45 The culmina-
tion of these anti-inflammatory properties of statins
is reflected in their ability to reduce the levels of
C-reactive protein (CRP),46 a marker of systemic
inflammation associated with increased cardiovascu-
lar and cerebrovascular risk.47
Fig. 2. G-protein mediated effects on inflammatory and endothelial cell function. Once activated, inflammatory cells interact
with and adhere to the endothelium, mediated by selectins, integrins, VCAM-1 and ICAM-1. IL-1 and IL-8 are potent
chemotactic agents for inflammatory cells, effects mediated by RhoA. The G protein, Rac mediates the formation of
lamellopodia, necessary for cell migration. RhoA and Rac modify polymerisation of actin, producing changes in the
endothelial cell cytoskeleton necessary for cellular adhesion. Activation of Rho results in stress-fibre formation, retraction
and facilitation of neutrophil migration and endothelial cell contraction. Vasoconstrictors, including thrombin, activate
Rho-A, inducing Ca2þ sensitisation, contraction of smooth muscle cells (SMC), vasospasm and hypertension. Cellular
responses mediated by G-protein are boxed.
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Smooth muscle cell proliferation
SMC proliferation and migration occurs during primary
arteriosclerosis, post angioplasty re-stenosis, in trans-
plant arteriosclerosis and in neointimal hyperplasia.48
The products of mevalonate metabolism are essential for
SMC proliferation.49 Statins decrease the rate of pro-
liferation of SMCs in vitro and in vivo50 and reduce
metalloproteinase expression and secretion (see below),
a pre-requisite for SMC-proliferation and migration.51
Plaque instability
The unstable atherosclerotic plaque leads to acute
coronary syndromes.52 The features of plaque instabil-
ity and susceptibility to rupture include a thin fibrous
cap, low collagen content, few SMCs, increased foam
cells, monocytes and macrophages and large amounts
of fibrin and haemorrhage.53 Plaques rich in foam cells
are unable to absorb transmitted energy54 and although
these plaques only represent 10–20% of lesions, they are
responsible for 80–90% of acute clinical events.55 This
may explain the association between echo-lucent lipid
laden plaques and the increased risk of stroke.56
Statins inhibit LDL oxidation, lipid accumulation,
macrophage infiltration and increase the collagen
content of atherosclerotic plaques.57
The proteolytic imbalance (metalloproteinases)
Matrix metalloproteinases (MMPs) are an endogenous
Ca2þ and Zn2þ-dependent group of proteolytic
Fig. 3. Pleiotropic effects of statins on endothelial cell function. Statins inhibit a range of cellular responses to inflammation,
including inhibition of NFkB activity, leading to decreased transcription of MMP, adhesion molecule and cytokine genes.
Binding of adhesion molecules to endothelial cell surface receptors is blocked and receptor clustering is decreased. Secretion
of MMPs from activated neutrophils is also inhibited by statins. In the endothelium, levels of expression of eNOs mRNA are
increased and eNOs is activated while expression of endothelin-1 is inhibited. Calcium mobilisation in smooth muscle cells is
also inhibited, leading to reductions in proliferation and migration of these cells. Cellular pathways inhibited by statins are
boxed.
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enzymes. Together with their endogenous inhibitors,
the tissue inhibitors of metalloproteinases (TIMPs),
they are responsible for homeostasis of the extra-
cellular matrix. Collagen, a major component of the
fibrous cap (40% of the total protein), is responsible for
its tensile strength. Impaired collagen synthesis or
increased proteolysis increases the susceptibility of the
cap to rupture.52 MMPs play a prominent role in
atherosclerosis and have been implicated in plaque
instability and rupture.58 Lipid-lowering and statin
therapy reduce MMP activity and increase the
collagen content of atheromatous plaques,59 effects
known to improve plaque stability. As well as lipid
lowering, statins also decrease the expression of
MMPs.60
Thrombosis, platelets, clotting and fibrinolysis
Hypercholesterolaemia is associated with hyper-
coagulability and increased platelet reactivity and
sensitivity,61 thus playing a critical role in acute
coronary syndromes.62 Statins attenuate platelet acti-
vation via up-regulation of eNOS63 and reduce
macrophage expression of tissue factor (TF),64 an
important determinant of plaque thrombogenicity.
Combining these effects decreases thrombin gener-
ation and thrombus formation.65 Hypercholesterola-
mia is also associated with hypofibrinolytic states.66
Statins enhance the fibrinolytic capacity of endothelial
cells by increasing the levels of expression of tissue
plasminogen activator (t-PA) or by decreasing plas-
minogen activator inhibitor-1 (PAI-1) activity,67 attenu-
ating the thrombotic response to plaque rupture.68 A
comparative study demonstrated that statins (with
the exception of pravastatin) increased t-PA and
decreased PAI-1 favouring fibrinolysis in vitro.69
Although the full clinical implications have not yet
been clarified, attenuation of platelet activation and
amelioration of the thrombotic/fibrinolytic response
to plaque rupture may explain in part, the early
benefits of statin therapy.70
Clinical Relevance
Statins, cardiovascular disease and vascular patients
Guidelines for the primary and secondary prevention
of coronary artery disease (CAD) by the lowering of
LDL cholesterol are well-established.71 The efficacy of
statins in the prevention of CAD events has been
demonstrated in five randomised placebo controlled
trials involving a total of 30,817 patients.21,72 – 75
Treatment for 5 years reduces the risk of major
coronary events by 34 and 30% in primary and
secondary prevention, respectively. However, LDL
cholesterol levels only identify 50% of patients who
will die from CAD with a 46% sensitivity of predicting
10 year CAD death rates.76 In addition, the predicted
CAD event risk rate reduction, based on LDL lower-
ing, is underestimated by approximately 35%.20 These
benefits occur regardless of plaque regression,55 in
patients with normal cholesterol and after a relatively
short period of time, implicating the non-sterol effects
of statins as being responsible for their early clinical
benefits.77
Clinically significant CAD is present in 70% of
patients with intermittent claudication (10 year
mortality from M.I. and CVA of 50%),78 50% of
patients with abdominal aortic aneurysms (ischaemia
in 35% following repair) and in over 30% of patients
with carotid disease (annual cardiac mortality of 6.5%
in patients with .75% stenosis).79 Patients with
critical limb ischaemia (CLI) have a dismal prognosis,
with a 20% 1 year cardiac mortality.80 This high
prevalence of CAD and incidence of cardiac events
places vascular patients in an at risk group eligible for
primary intervention.
Statins, cerebrovascular disease and ongoing trials
Ischaemic stroke is the third leading cause of death in
the USA, however hypercholesterolaemia is not
considered to be a significant risk factor in the
pathogenesis of stroke.81 The multiple risk factor
intervention trial (MRFIT) failed to demonstrate a
significant correlation between hypercholesterolaemia
and stroke82 but others have demonstrated a protec-
tive effect.83 In two meta-analyses of approximately
400 strokes in 40,000 participants from 13 clinical trials
of non-statin cholesterol lowering agents, there was no
reduction in the risk of stroke associated with
cholesterol lowering.84,85 Despite this, recent studies
have demonstrated that statins significantly reduce the
incidence of ischaemic stroke in patients with estab-
lished CAD.86 Meta-analysis of randomised, placebo-
controlled double blind trials demonstrates benefits in
the middle aged.87 The relative risk reduction of
cerebrovascular events was 28% in the 4S Study, 31%
(P , 0:03) in the CARE study88 and 19% (P , 0:048) in
the LIPID Study.89 Benefits were greatest in patients
who were elderly, diabetic, hypertensive, had pre-
served LVEF and in those with no history of previous
TIA or Stroke.88 The multi-disciplinary consensus
statement from the National Stroke Association has
since recommended the use of cholesterol lowering
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with statins to reduce the risk of stroke after
myocardial infarction.90
Further trials may elucidate other potential
candidates for statin therapy. The PROSPER study
will examine the effects of statins on cognitive
decline, MI, stroke and death in elderly patients
with pre-existing vascular disease.91 The SPARCL
trial will examine the effects of atorvastatin on
patients with previous TIA or Stroke92 and the
RESPECT trial will examine patients without cardio-
vascular disease but at high risk of stroke.
In addition to the above benefits, epidemiological
studies have also identified a strong independent
association between extra cranial carotid intimal-
medial thickness,93 the degree of stenosis and inci-
dence of stroke.94,95 Statins produce significant
reductions in carotid intimal-medial thickness89,96
and decrease aortic atherosclerosis,97 a known source
of cerebral embolization.98
Statins and peripheral vascular disease
A recent review by the Cochrane peripheral vascular
disease group identified only seven suitable random-
ised trials of lipid lowering therapy (not statins) in
patients with lower limb atherosclerosis.99 Lipid
lowering therapy produced a marked but non-
significant reduction in mortality and little change in
non-fatal events. Only two of the trials showed a
significant reduction in disease progression on angio-
gram with changes in ankle-brachial pressure indices
(ABPI) and claudication distance being inconsistent.
The collaboration concluded that future trials of PVD
should include outcomes specifically relevant to the
lower limb, including progression to surgical and
radiological intervention. Although none of the above
trials used a statin, the Scandinavian Simvastatin
Survival Study (4S) demonstrated a statistically signi-
ficant reduction in new or worsening intermittent
claudication in those on treatment after 3 years, from
3.6% in the placebo group to 2.3% in the simvastatin
group.100
Statins and transplantation
Statins influence rejection following cardiac or renal
transplantation by inhibition of T and B-lymphocyte
activity,101,102 decreasing acute rejection, coronary
vasculopathy and NK cell cytotoxicity.103,104 These
effects have been shown to prevent accelerated graft
atherosclerosis and improve allograft and patient
survival.104 – 106
Independent review (guidelines for lipid reduction)
The Lipid Working Group recommends total lipid
profiling as a means to identify and reduce the risk of
CAD. The importance of HDL has recently been
recognised and an estimate of risk should include
the ratio TC: HDL-C. Low HDL is associated with the
atherogenic form of LDL. The cardiovascular risk of
low HDL may in fact be more relevant than high LDL.
The doctors and pharmacists consumers association
have published an independent review suggesting
guidelines for primary and secondary prevention of
CAD including therapeutic goals.107 Only 30% of
patients with established CAD and raised serum lipids
and fewer than 4% of individuals eligible for primary
prevention of CAD currently receive lipid-lowering
therapy. This poor performance of risk factor manage-
ment has been emphasised in a survey of vascular
surgeons108 and confirmed in more recent communi-
cations.109,110 Recommendations that all patients with
clinically overt atherosclerotic cardiac disease and
those patients with an estimated risk of a significant
cardiac event (fatal or non-fatal MI plus angina) of
above 30% over 10 years should be started on a statin.
This should include those with a 15% risk over 10
years as resources permit. Guidelines were to lower
total cholesterol to below 5 mmol/l or by 30–35% or
LDL-cholesterol concentrations to below 3 mmol/l or
by 30%.
Heart protection study
The Heart Protection Study is an extensive survey of
over 20,000 UK patients aged between 40–80 with a
mean follow up of over 5 years.111 Simvastatin (40 mg)
was compared to placebo and showed benefit across
all patient groups regardless of age, gender or baseline
cholesterol. Total mortality was reduced by 12% with
a reduction in vascular mortality, CAD events (fatal
and non-fatal MI) and strokes of 17, 24, and 27%
respectively. There was also a reduction in non-
coronary revascularization of 16% and a reduction in
the number of patients requiring carotid endarterect-
omy (CEA) of almost 50%. There was no threshold
below which statin therapy failed to show benefit.
Future Research
Statins in ischaemia reperfusion injury (IRI)
As discussed above, statins inhibit the expression
of cytokines, adhesion molecules, proteases and
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superoxides and decrease neutrophil chemotaxis and
endothelial interactions, all major players in the patho-
genesis of IRI. These effects of statins have been shown
to attenuate cerebral,30 cardiac112,113 and renal IRI114
and are likely to apply equally to skeletal muscle IRI
(Laws et al, 2003, submitted for publication).
Neo-intimal hyperplasia
Statins accelerate re-endothelialisation and attenuate
neointimal formation in vitro and in vivo.115,116 Statins
reduce the number of stenotic lesions and interven-
tions required to maintain patency following coronary
artery bypass grafting (CABG).117 It seems reasonable
to assume that the synergistic effects of statins will
improve primary patency rates following infra-
inguinal bypass surgery and hence reduce the need
for radiological and surgical intervention.
Statins in aneurysmal disease
Elevated cholesterol is associated with aneurysmal
disease118 and elevated triglycerides with an increased
likelihood of rupture.119 The cytokines IL-1 and TNF-a
are increased in AAA,120 as are macrophages and T
lymphocytes.121 MMPs secreted by macrophages have
been implicated in aneurysmal disease122,123 and
plasma MMP-9 is increased compared to controls.124
Cerivastatin decreases the accumulation of macro-
phages, inhibits the production of MMP-1, MMP-3 and
MMP-9 and increases the collagen content in aortic
atheroma.125 These attributes of statins may well
combine to attenuate the initiation and progression
of aneurysmal disease.
Statins cost implications (pharmacoeconomics)
In the United States 5.4% of the adult population
currently take a statin with atorvastatin becoming the
most frequently prescribed drug in the world. The cost
effectiveness of statins has been estimated at 8000 UK
pounds (11,500 Euros) per life year gained and varies
widely between the statins.126,127 Patients at higher
risk not surprisingly face greater potential absolute
benefit. The cost per event avoided in the MIRACL
trial (80 mg/day of atorvastatin vs. placebo initiated
after acute coronary syndrome (ACS)) amounts to 1762
UK pounds (2500 Euros).128 At the other end of the
spectrum, the WOSCOPS trial indicates that of 10,000
patients treated with a statin for 5 years, 9755 would
receive no benefit.129 Thus the higher the risk of an
event, the more cost-effective statin therapy becomes.
Conclusions
Statins beneficially alter the lipid profile of patients in
accordance with the Lipid Working Group recommen-
dations. They improve endothelial function, are anti-
inflammatory, anti-proliferative, anti-thrombogenic
and anti-proteolytic. These therapeutic effects not
only decrease the incidence of cardiovascular (34–
30%) and cerebrovascular events (19–37%) but also are
likely to attenuate such events should they occur.
Numerous independent groups have advocated their
use in the prevention of CAD and the National Stroke
association have recommended their use in the
prevention of stroke following myocardial infarction.
Data from the Heart Protection Study reports their
benefits in reducing the need for non-cardiac revascu-
larization by 16%. Future benefits may include a
decreased need for primary and secondary infra-
inguinal intervention (surgical and radiological), a
reduction in aneurysm progression and rupture and a
decrease in the morbidity and mortality from IRI. Even
if we ignore the mounting evidence advocating the use
of statins in vascular patients, the high prevalence of
CAD (30–70%) and incidence (particularly peri-
operative) of cardiac events in vascular patients places
them in an at risk group eligible for primary interven-
tion. Whether the health services of individual
countries will be able to meet the additional financial
burden of targeting this at risk group with what is
essentially preventative medicine remains to be seen.
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